Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.53 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.53 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | FABP7 | O15540 | 1/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13687204 | 0.91 | CHRNB2 (0.61) | CHRNB2CHRNB4CHRNA3CHRNA4HPGD | |
| SCHEMBL21724320 | 0.86 | KDM4E (0.47) | CHRNB2CHRNB4CHRNA3CHRNA4HPGD | |
| SCHEMBL31279443 | 0.86 | RIPK1 (0.54) | CHRNB2CHRNB4CHRNA3CHRNA4HPGD | |
| SCHEMBL3863448 | 0.86 | LTB4R (0.52) | HPGDALDH1A1KDM4EMAPTFABP7 | |
| SCHEMBL206007 | 0.85 | CHRNB2 (0.53) | CHRNB2CHRNB4CHRNA3CHRNA4HPGD | |
| SCHEMBL20683501 | 0.85 | CHRNB2 (0.53) | CHRNB2CHRNB4CHRNA3CHRNA4ALDH1A1 | |
| SCHEMBL28696201 | 0.83 | LMNA (0.53) | ALDH1A1NPC1LMNAL3MBTL1HDAC1 | |
| SCHEMBL28696202 | 0.83 | LMNA (0.53) | ALDH1A1NPC1LMNAL3MBTL1HDAC1 | |
| SCHEMBL2044105 | 0.83 | CHRNB2 (0.51) | CHRNB2CHRNB4CHRNA3CHRNA4HPGD | |
| SCHEMBL16980507 | 0.83 | MEN1 (0.68) | CHRNB2CHRNB4CHRNA3CHRNA4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024233838-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | RANOK THERAPEUTICS (HANGZHOU) CO. LTD. (CN) | 2024-11-14 | — | — | WO | disclosed |
| EP-2496558-B1 | TETRAHYDROQUINOLINES DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-03-30 | — | — | EP | disclosed |
| US-8580957-B2 | Thetrahydroquinolines derivatives as bromodomain inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580957-B2 | Thetrahydroquinolines derivatives as bromodomain inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580957-B2 | Thetrahydroquinolines derivatives as bromodomain inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120208814-A1 | Thetrahydroquinolines Derivatives As Bromodomain Inhibitors | GLAXOSMITHKLINE LLC | 2012-08-16 | — | — | US | disclosed |
| US-20120208814-A1 | Thetrahydroquinolines Derivatives As Bromodomain Inhibitors | GLAXOSMITHKLINE LLC | 2012-08-16 | — | — | US | disclosed |
| US-20120208814-A1 | Thetrahydroquinolines Derivatives As Bromodomain Inhibitors | GLAXOSMITHKLINE LLC | 2012-08-16 | — | — | US | disclosed |
| WO-2011054848-A1 | THETRAHYDROQUINOLINES DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208814-A1 | Thetrahydroquinolines Derivatives As Bromodomain Inhibitors | BRD4, BRDT, BRPF3 | CHRNB2 2063/4885CHRNB4 2814/4885CHRNA3 1301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.